Skip to content
Screener

Other geography segments

US
$172.34M+3.2%
FR
$7M-1.6%

Similar metrics at other companies

Unifi logo
UFICN — Revenue
$22.38M-2.5%
Alpha Cognition logo
ACOGCN — Revenue
$29.98K-98.8%
CBA
CBATCN — Revenue
$50.96M+58.7%
Weyerhaeuser logo
WYCN — Revenue
$2.75M-88.0%
Universal Display logo
OLEDCN — Revenue
$43.64M-38.6%
Cabot Corporation logo
CBTCN — Revenue
$232.75M-5.3%

Other financials

Income statement

See full
Revenue$183.9M+5.4%
Gross profit$93.5M+8.1%
Operating income$39.7M-5.8%
Net income$30.3M-2.2%
EPS (diluted)$0.67+4.7%

Balance sheet

See full
Cash & equivalents$223.6M+19.1%
Total debt$688.5M+5.0%
Total equity$445.5M
Total assets$1.7B+8.0%

Cash flow

See full
Operating cash flow$51.3M+44.2%
CapEx$8.6M-18.7%
Free cash flow$42.7M+70.7%

Valuation

See full
Market cap$916.25M-28.0%
Enterprise value$1.38B-20.6%
P/E11.7×+2.2×
P/S1.3×-0.5×

Profitability

See full
Gross margin47.7%-2.2pp
Operating margin15.7%-9.5pp
Net margin10.8%-7.9pp
FCF margin20.9%+5.4pp

Returns & leverage

See full
Return on equity14.7%
Debt / equity0.2×
Current ratio2.4×-0.9×

Where this comes from

Reported directly by Amphastar Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:Revenues.

The source filing: Amphastar Pharmaceuticals’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 4:50 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001297184-26-000047
Line itemNet Revenues / Three Months Ended / June 30, 2026Net Revenues / Three Months Ended / June 30, 2025Net Revenues / Six Months Ended / June 30, 2026Net Revenues / Six Months Ended / June 30, 2025Long-Lived Assets / June 30, 2026Long-Lived Assets / December 31, 2025
United States$172,342$167,002$331,382$329,592$247,218$206,697
China4,5602997,042380107,268110,055
France7,0017,11316,65014,97034,64036,967
Total$183,903$174,414$355,074$344,942$389,126$353,719

Item 1. Financial Statements (unaudited)

FAQ

What is Amphastar Pharmaceuticals's CN — revenue?
Amphastar Pharmaceuticals (AMPH) reported CN — revenue of $4.56M in Q2 2026.
How has Amphastar Pharmaceuticals's CN — revenue changed year-over-year?
Amphastar Pharmaceuticals's CN — revenue increased by 1425.1% year-over-year, from $299K to $4.56M.
What is the long-term trend for Amphastar Pharmaceuticals's CN — revenue?
Over 4 years (2021 to 2025), Amphastar Pharmaceuticals's CN — revenue has grown at a -14.7% compound annual growth rate (CAGR), from $6.02M to $3.18M.
What does CN — revenue mean?
This metric represents the total gross income generated from the sale of goods and services within the specified geographic or operational segment. It serves as a primary indicator of market demand and the commercial success of the company's product portfolio in this specific region. Tracking this revenue stream helps investors evaluate the segment's contribution to overall corporate growth and its ability to maintain market share.

Ask your AI about Amphastar Pharmaceuticals's cn — revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude